In the November 2015 issue of The Cheap Investor, we made a recommendation to pick up shares of CPXX at just $1.75 a share. Just months later, the stock skyrocketed to a high of $17.69 for potential gains of 911% on news of successful Phase III clinical results for VYXEOS for patients with high risk of acute myeloid leukemia (AML). Not only is this exciting news for shareholders, but for the thousands of patients that must deal with AML.
According to a March 2016 press release, “The median overall survival for patients treated with VYXEOS in the study was 9.56 months compared to 5.95 months for patients receiving 7+3, representing a 3.61 month improvement in favor of VYXEOS. The hazard ratio (HR) was 0.69 (p=0.005) which represents a 31 percent reduction in the risk of death versus 7+3. The percentage of patients alive 12 months after randomization was 41.5% on the VYXEOS arm compared to 27.6% on the 7+3 arm. The percentage of patients alive 24 months after randomization was 31.1% on the VYXEOS arm compared to 12.3% on the 7+3 arm.”
Every $5,000 risked on CPXX in November 2015 is now worth $50,550. Not bad at all.